However, a gradual taper under provider guidance may help the body adjust more slowly and can make the transition easier to manage, particularly for patients concerned about rapid hunger return
Patients with insulin resistance, metabolic dysfunction, or inadequate response to GLP-1 therapy may benefit more
Proponents of this approach say it can have health benefits with fewer side effects and reduced costs
Experimental studies suggest it may also have mild anticoagulant effects by inhibiting clotting factors

Frequently Asked Questions References FDA: Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss - FDA guidance on semaglutide products, including compounded and counterfeit risk warnings FDA: Compounding and the FDA, Questions and Answers - FDA explanation of 503A and 503B compounding rules and quality oversight FDA: Approves New Medication (Wegovy/semaglutide) for Chronic Weight Management - FDA approval record for semaglutide (Wegovy) for chronic weight management NovoCare: Wegovy Cost and Coverage Support - NovoCare self-pay and coverage support figures for branded Wegovy NovoCare: Wegovy Savings Offer and Self-Pay Pricing - NovoCare published Wegovy self-pay price used for the 12-month cost table Wegovy (semaglutide) Official Site, Novo Nordisk - Manufacturer Wegovy site for branded dosing and list-price context Cleveland Clinic: GLP-1 Agonists Overview - Cleveland Clinic clinical overview of how GLP-1 receptor agonists work and safety JAMA Network Open: Weight Loss Outcomes Associated With Semaglutide Treatment - Peer-reviewed semaglutide weight-loss outcomes supporting efficacy figures Medical Disclaimer: This article is for general educational purposes only and is not medical advice

This integrated approach ensures a holistic treatment, addressing not just the symptoms of depression or anxiety but also safeguarding against the risks of addiction